Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed (PDF) that Walmsley took a 16% pay cut in 2024, it also laid out a new compensation ...

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

GSK plc (NYSE:GSK) Price Target Upside: 29.94% GSK plc (NYSE:GSK), formerly known as GlaxoSmithKline, is a global pharmaceutical and healthcare corporation based in the United Kingdom that creates ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other ...

Shares of GlaxoSmithKline Pharmaceuticals (GSK Pharma) extended their rally for the second consecutive session on Tuesday (February 18), gaining 29% over two days. The stock had hit a 20% upper ...

The rally in GlaxoSmithKline Pharmaceuticals shares comes after the company reported robust growth in its Q3 results. The biopharma company reported its earnings for the third quarter of FY25 on ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd. are trading with gains of 20% on Monday, February 17, bucking in trend in a market where most Nifty 50 constituents are trading with losses. GSK Pharma ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

In addition to vaccines, GSK Pharma would also be introducing innovative drugs to treat endometrial and ovarian cancer. However, the current valuation captures the earnings upside. Maintain Neutral.